ClinicalTrials.gg
RecruitingNCT06980428Updated Nov 2, 2026

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia

A Phase 1 interventional study of AZD4954 and Placebo in Healthy Participants and Dyslipidemia, sponsored by AstraZeneca. Recruiting at 6 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.
Updated Nov 2, 2026Enrollment updatedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
171
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies in Dyslipidemias by AstraZeneca — 1 open to participants now, 3 under way, 1 of them phase 3. Dyslipidemias · AstraZeneca.

Planned enrollment
18th of 37
171 · median 119
Started
2025
with 2 others
Phase 1
16 of 57
1 open now
Registered
51st of 57
by date

Among the 57 studies in Dyslipidemias by AstraZeneca, this one is the 18th largest by planned enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2025, is one of 16 in phase 1, and was the 51st registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

1 of the 57 studies in Dyslipidemias by AstraZeneca is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Dyslipidemias by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of AZD4954 in healthy participants with or without elevated Lipoprotein(a) (Lp[a]) levels and participants with dyslipidemia.

Read the detailed description

This is a first time in human, placebo-controlled, single and multiple ascending dose (SAD and MAD) study in healthy male and female participants (Part A) or healthy participants with elevated Lp(a) levels (≥ 30 mg/dL, [62 nmol/L]) and participants with dyslipidemia with elevated Lp(a) levels (≥ 70 mg/dL, [150 nmol/L]) and low-density lipoprotein cholesterol (LDL-C) ≥ 70 mg/dL and \< 190 mg/dL (Part B).

The study consists of 2 parts: Part A (SAD) and Part B (MAD).

Part A of the study will consist of Part A1 and Part A2, comprising:

  • A Screening Period of maximum 28 days.
  • Admission to study site (Day -1).
  • A Treatment Period (Day 1 to Day 15 at the study site) with a single dose of AZD4954 or placebo on Day 1.
  • A Follow-up Visit within 26 to 30 days after the study intervention dose for all cohorts (Day 29 ±2 days).

Part B has 3 types of MAD cohorts - global cohorts with healthy participants, global cohort with participants with dyslipidemia, and a Japanese cohort. The global MAD cohorts (healthy participants) and Japanese MAD cohort will comprise:

  • A Screening Period of maximum 28 days.
  • Admission to study site (Day -1).
  • A Treatment Period during which participants will receive either AZD4954 or placebo once daily for 21 days (Day 1 to 21).
  • A Follow-up Visit within 26 to 30 days after the last study intervention dose (Day 49 ±2 days).

The global MAD cohort (participants with dyslipidemia) will comprise:

  • A Screening Period of maximum 28 days.
  • Residential study site visits from Day -1 to Day 2 and Day 21 to Day 22.
  • Non-residential study site visits on Day 8 and Day 15.
  • A Treatment Period during which participants will receive either AZD4954 or placebo once daily for 21 days (Day 1 to 21).
  • A Follow-up Visit within 26 to 30 days after the last study intervention dose (Day 49 ± 2 days).
03

Conditions studied

  • Healthy Participants
  • Dyslipidemia

Browse trials for

Keywords

  • Lipoprotein(a)
  • Low-density lipoprotein cholesterol (LDL-C)
04

Who can participate

The criteria were revised on the registry on Nov 2, 2026. See what changed

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Parts:

  • Participants with plasminogen level (concentration) within normal range at the Screening Visit.
  • All females must have a negative pregnancy test at the Screening Visit and on admission to the study site.
  • Females of must not be lactating and if heterosexually active must agree to use an approved method of highly effective .
  • Females of non-childbearing potential must be confirmed at the Screening Visit.
  • Sexually active fertile male participants with partners of childbearing potential must adhere to the study specific contraception methods from the time of first administration of study intervention until 3 months after the study Follow-up Visit.

Parts A and B (Healthy Participants):

  • Male and female participants aged 18 to 65 years with suitable veins for cannulation or repeated venipuncture.
  • Have a (BMI) between 18 and 35 kg/m² inclusive.
  • For Japanese and Chinese participants (Parts A and B):

    1. A Japanese participant is defined as having both parents and 4 grandparents who are ethnically Japanese. This includes second and third generation Japanese whose parents or grandparents are living in a country other than Japan.
    2. A Chinese participant is defined as having both parents and 4 grandparents who are ethnically Chinese. This includes second and third generation Chinese whose parents or grandparents are living in a country other than China.

      Part B (Healthy Participants):

  • Participants must have elevated Lp(a) ≥ 30 mg/dL (62 nmol/L) at the Screening Visit.

Part B (Participants with Dyslipidemia):

  • Male and female participants aged 18 to 70 years with suitable veins for cannulation or repeated venipuncture.
  • Have a BMI > 18 kg/m².
  • Participants must have elevated Lp(a) ≥ 70 mg/dL (150 nmol/L) at the Screening Visit.
  • Participants with a fasting LDL-C ≥ 70 mg/dL and \< 190 mg/L at the Screening Visit.
  • Participants should be receiving moderate or high-intensity statin therapy for ≥ 2 months prior to the Screening Visit, according to the American College of Cardiology/American Heart Association guidelines on blood cholesterol management.
  • Participants with documented coronary artery disease, stroke, or peripheral artery disease or at moderate or high risk for an atherosclerotic cardiovascular disease event.
  • There should be no planned medication or dose change during study participation.

Exclusion criteria

Exclusion Criteria:

All Parts:

  • History of any disease or disorder.
  • History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
  • Participants with known bleeding or coagulation disorders.
  • Participants who have an elevated high-sensitivity C-reactive protein (> 3 mg/L) or have a /international normalized ratio (PT/INR) or activated partial thromboplastin time (aPTT) > 1.25 times × upper limit normal ().
  • Any clinically important abnormalities in hematology, coagulation, clinical chemistry, urinalysis, abnormal vital signs or abnormal laboratory values.
  • Any positive result on Screening for serum surface antigen (HBsAg), hepatitis B core antibody (HBcAb), virus (HCV) or (HIV).
  • Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12-lead (ECG) at Screening.
  • Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of study intervention.

Parts A and B (Healthy Participants):

  • Use of any prescribed or nonprescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, intake of > 3 × daily recommended levels of vitamins and minerals during the 2 weeks prior to the first administration of study intervention or longer if the medication has a long half-life.
  • Current smokers or those who have smoked or used nicotine products.

Part B (Participants with Dyslipidemia):

  • Acute ischemic cardiovascular event in the last 12 months prior to randomization.
  • Poorly controlled diabetes.
  • Previous administration of Lp(a) inhibitor.
  • Have uncontrolled hypertension.
  • Abnormal vital heart rate.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
171 participants (estimated)

Study arms

  • Experimental
    Part A1: SAD Cohort 1 - AZD4954 (Dose 1)

    Participants will receive a single dose of AZD4954 (Dose 1) or matching placebo on Day 1.

    Drug: AZD4954 · Drug: Placebo

  • Experimental
    Part A1: SAD Cohort 2 - AZD4954 (Dose 2)

    Participants will receive a single dose of AZD4954 (Dose 2) or matching placebo on Day 1.

    Drug: AZD4954 · Drug: Placebo

  • Experimental
    Part A1: SAD Cohort 3 - AZD4954 (Dose 3)

    Participants will receive a single dose of AZD4954 (Dose 3) or matching placebo on Day 1.

    Drug: AZD4954 · Drug: Placebo

  • Experimental
    Part A1: SAD Cohort 4 - AZD4954 (Dose 4)

    Participants will receive a single dose of AZD4954 (Dose 4) or matching placebo on Day 1.

    Drug: AZD4954 · Drug: Placebo

  • Experimental
    Part A1: SAD Cohort 5 - AZD4954 (Dose 5)

    Participants will receive a single dose of AZD4954 (Dose 5) or matching placebo on Day 1.

    Drug: AZD4954 · Drug: Placebo

  • Experimental
    Part A1: SAD Optional Cohort 6 - AZD4954

    This additional cohort may be added depending on the findings.

    Drug: AZD4954 · Drug: Placebo

  • Experimental
    Part A1: SAD Cohort 1 (Japanese) - AZD4954 (Dose 2)

    Japanese participants will receive a single dose of AZD4954 (Dose 2) or matching placebo on Day 1.

    Drug: AZD4954 · Drug: Placebo

  • Experimental
    Part A1: SAD Cohort 2 (Japanese) - AZD4954 (Dose 3)

    Japanese participants will receive a single dose of AZD4954 (Dose 3) or matching placebo on Day 1.

    Drug: AZD4954 · Drug: Placebo

  • Experimental
    Part A1: SAD Optional Cohort 3 (Japanese) - AZD4954

    This additional cohort may be added depending on the findings.

    Drug: AZD4954 · Drug: Placebo

  • Experimental
    Part A1: SAD Cohort 1 (Chinese) - AZD4954 (Dose 5)

    Chinese participants will receive a single dose of AZD4954 (Dose 5) or matching placebo at the highest dose level on Day 1.

    Drug: AZD4954 · Drug: Placebo

  • Experimental
    Part A2: SAD Food Effect Cohort - AZD4954 (Dose 2)

    Participants will receive a single dose of AZD4954 (Dose 2) or matching placebo with a high-calorie, high-fat breakfast on Day 1.

    Drug: AZD4954 · Drug: Placebo

  • Experimental
    Part A2: SAD Food Effect Cohort - AZD4954 (Dose 3)

    Participants will receive a single dose of AZD4954 (Dose 3) or matching placebo with a high-calorie, high-fat breakfast on Day 1.

    Drug: AZD4954 · Drug: Placebo

  • Experimental
    Part B: Global MAD Cohort 1 (healthy participants) - AZD4954 (Dose 1)

    Participants will receive multiple doses of AZD4954 (Dose 1) or matching placebo for 21 days.

    Drug: AZD4954 · Drug: Placebo

  • Experimental
    Part B: Global MAD Cohort 2 (healthy participants) - AZD4954 (Dose 2)

    Participants will receive multiple doses of AZD4954 (Dose 2) or matching placebo for 21 days.

    Drug: AZD4954 · Drug: Placebo

  • Experimental
    Part B: Global MAD Cohort 3 (healthy participants) - AZD4954 (Dose 3)

    Participants will receive multiple doses of AZD4954 (Dose 3) or matching placebo for 21 days.

    Drug: AZD4954 · Drug: Placebo

  • Experimental
    Part B: Optional Global MAD Cohort 4 (healthy participants) - AZD4954

    Participants will receive multiple doses of AZD4954 or matching placebo for 21 days. This additional cohort may be added depending on the findings.

    Drug: AZD4954 · Drug: Placebo

  • Experimental
    Part B: Optional Global MAD Cohort 5 (healthy participants) - AZD4954

    Participants will receive multiple doses of AZD4954 or matching placebo for 21 days. This additional cohort may be added depending on the findings.

    Drug: AZD4954 · Drug: Placebo

  • Experimental
    Part B: Optional Global MAD Cohort 6 (healthy participants) - AZD4954

    Participants will receive multiple doses of AZD4954 or matching placebo for 21 days. This additional cohort may be added depending on the findings.

    Drug: AZD4954 · Drug: Placebo

  • Experimental
    Part B: MAD Cohort (Japanese) - AZD4954 (Dose 3)

    Japanese participants will receive multiple doses of AZD4954 (Dose 3) or matching placebo for 21 days.

    Drug: AZD4954 · Drug: Placebo

  • Experimental
    Part B: Global MAD Cohort (participants with dyslipidemia) - AZD4954 (Dose 6)

    Participants with dyslipidemia will receive multiple doses of AZD4954 (Dose 6) or matching placebo for 21 days.

    Drug: AZD4954 · Drug: Placebo

Interventions

  • AZD4954 will be administered orally.

  • DrugPlacebo

    Placebo will be administered orally.

06

What researchers measure

Primary outcomes

  1. Part A: Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    To assess the safety and tolerability of AZD4954 following oral administration of SAD (Part A).

    Time frame: From Screening (Day -28 to Day -2) to Follow-up visit (Up to Day 29±2 days)

  2. Part B: Number of participants with AEs and SAEs

    To assess the safety and tolerability of AZD4954 following oral administration of MAD (Part B).

    Time frame: From Screening (Day -28 to Day -2) to Follow-up visit (Up to Day 49±2 days)

Secondary outcomes

  1. Part A: Area under concentration-time curve from time 0 to infinity (AUCinf)

    To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.

    Time frame: Up to Day 29±2 days

  2. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)

    To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.

    Time frame: Part A: Up to Day 29±2 days; Part B: Up to Day 49±2 days

  3. Part B: Area under concentration-time curve in the dosing interval (AUCtau)

    To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.

    Time frame: Up to Day 49±2 days

  4. Dose normalized AUClast (AUClast/D)

    To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.

    Time frame: Part A: Up to Day 29±2 days; Part B: Up to Day 49±2 days

  5. Dose normalized AUCinf (AUCinf/D)

    To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.

    Time frame: Part A: Up to Day 29±2 days; Part B: Up to Day 49±2 days

  6. Part B: Dose normalized AUCtau (AUCtau/D)

    To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.

    Time frame: Up to Day 49±2 days

  7. Apparent total body clearance (CL/F)

    To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.

    Time frame: Part A: Up to Day 29±2 days; Part B: Up to Day 49±2 days

  8. Maximum observed drug concentration (Cmax)

    To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.

    Time frame: Part A: Up to Day 29±2 days; Part B: Up to Day 49±2 days

  9. Dose normalized Cmax (Cmax/D)

    To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.

    Time frame: Part A: Up to Day 29±2 days; Part B: Up to Day 49±2 days

  10. Terminal elimination half-life (t1/2λz)

    To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.

    Time frame: Part A: Up to Day 29±2 days; Part B: Up to Day 49±2 days

  11. Time of last quantifiable concentration (tlast)

    To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.

    Time frame: Part A: Up to Day 29±2 days; Part B: Up to Day 49±2 days

  12. Time to reach maximum observed concentration (tmax)

    To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.

    Time frame: Part A: Up to Day 29±2 days; Part B: Up to Day 49±2 days

  13. Apparent volume of distribution based on the terminal phase (Vz/F)

    To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.

    Time frame: Part A: Up to Day 29±2 days; Part B: Up to Day 49±2 days

  14. Individual and cumulative amount of unchanged drug excreted into urine from time t1 to time t2 (Ae[t1-t2])

    To characterize the single dose and/or steady state urine pharmacokinetics of AZD4954 following oral administration of AZD4954.

    Time frame: Part A: Up to Day 15; Part B: Up to Day 22

  15. Cumulative amount of unchanged drug excreted into urine (Aeinf)

    To characterize the single dose and/or steady state urine pharmacokinetics of AZD4954 following oral administration of AZD4954.

    Time frame: Part A: Up to Day 15; Part B: Up to Day 22

  16. Individual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 (fe[t1-t2])

    To characterize the single dose and/or steady state urine pharmacokinetics of AZD4954 following oral administration of AZD4954.

    Time frame: Part A: Up to Day 15; Part B: Up to Day 22

  17. Renal clearance (CLR)

    To characterize the single dose and/or steady state urine pharmacokinetics of AZD4954 following oral administration of AZD4954.

    Time frame: Part A: Up to Day 15; Part B: Up to Day 22

  18. Part B: Absolute change from baseline in serum Lp(a)

    To evaluate the pharmacodynamics of AZD4954 by assessment of Lp(a) levels following repeated oral dosing.

    Time frame: Up to Day 49±2 days

  19. Part B: Relative change from baseline in serum Lp(a)

    To evaluate the pharmacodynamics of AZD4954 by assessment of Lp(a) levels following repeated oral dosing.

    Time frame: Up to Day 49±2 days

  20. Part B: Absolute change from baseline in Lp(a) intact assay

    To evaluate the pharmacodynamics of AZD4954 by assessment of Lp(a) levels following repeated oral dosing.

    Time frame: Up to Day 49±2 days

  21. Part B: Relative change from baseline in Lp(a) intact assay

    To evaluate the pharmacodynamics of AZD4954 by assessment of Lp(a) levels following repeated oral dosing.

    Time frame: Up to Day 49±2 days

07

Study locations

6 of 6 sites recruiting
  • Research Site
    Glendale, California 91206, United States
    Recruiting
  • Research Site
    Inverness, Florida 34452, United States
    Recruiting
  • Research Site
    Jacksonville, Florida 32216, United States
    Recruiting
  • Research Site
    Port Orange, Florida 32127, United States
    Recruiting
  • Research Site
    Brooklyn, Maryland 21225, United States
    Recruiting
  • Research Site
    San Antonio, Texas 78229, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Apr 2027, 22 months after the start.

Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's planned 22 months is above that.

Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2025
First posted
May 20, 2025
StartActual
May 27, 2025
Primary completionEst.
Apr 9, 2027
CompletionEst.
Apr 9, 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
136→171
Nov 2, 2026
Eligibility
2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedParticipants must have elevated Lp(a) ≥ 30 mg/dL (62 nmol/L) at the Screening Visit.
  • EditedParticipants must have elevated Lp(a) ≥ 70 mg/dL (150 nmol/L) at the Screening Visit.
Nov 2, 2026
Interventions
Arm changed Part A1: SAD Optional Cohort 6 - AZD4954 (Dose 6)→Part A1: SAD Optional Cohort 6 - AZD4954; Part B: Global MAD Cohort (participants with dyslipidemia) - AZD4954 (Dose 1)→Part B: Optional Global MAD Cohort 5 (healthy participants) - AZD4954. Arms added: Part B: Optional Global MAD Cohort 6 (healthy participants) - AZD4954·Part B: Global MAD Cohort (participants with dyslipidemia) - AZD4954 (Dose 6)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Enrollment 136→171
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedParticipants must have elevated Lp(a) ≥ 30 mg/dL (62 nmol/L) at the Screening Visit.
    • EditedParticipants must have elevated Lp(a) ≥ 70 mg/dL (150 nmol/L) at the Screening Visit.
    Interventions Arm changed Part A1: SAD Optional Cohort 6 - AZD4954 (Dose 6)→Part A1: SAD Optional Cohort 6 - AZD4954; Part B: Global MAD Cohort (participants with dyslipidemia) - AZD4954 (Dose 1)→Part B: Optional Global MAD Cohort 5 (healthy participants) - AZD4954. Arms added: Part B: Optional Global MAD Cohort 6 (healthy participants) - AZD4954·Part B: Global MAD Cohort (participants with dyslipidemia) - AZD4954 (Dose 6)
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06980428
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 20, 2025
Start date
May 27, 2025
Primary completion
Apr 9, 2027 (estimated)
Completion
Apr 9, 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD4954

Start the discussion